Ultralow Defect Density at Sub-0.5 nm HfO2/SiGe Interfaces via Selective Oxygen Scavenging
Kavrik, Mahmut S, Thomson, Emily, Chagarov, Evgueni, Tang, Kechao, Ueda, Scott T, Hou, Vincent, Aoki, Toshihiro, Kim, Moon, Fruhberger, Bernd, Taur, Yuan, McIntyre, Paul C, Kummel, Andrew C
Published in ACS applied materials & interfaces (12.09.2018)
Published in ACS applied materials & interfaces (12.09.2018)
Get full text
Journal Article
Quantifying alcohol audio-visual content in UK broadcasts of the 2018 Formula 1 Championship: a content analysis and population exposure
Barker, Alexander, Opazo-Breton, Magdalena, Thomson, Emily, Britton, John, Grant-Braham, Bruce, Murray, Rachael L
Published in BMJ open (07.08.2020)
Published in BMJ open (07.08.2020)
Get full text
Journal Article
741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies
Papadopoulos, Kyriakos P, Laurie, Scott A, Spira, Alexander, Fu, Siqing, Hamilton, Erika, Ma, Brigette, Wang, Judy S, Sharma, Manish, Chu, Quincy, Spreafico, Anna, Bray, Mark R, Chen, Dih-Yih, Roberts-Thomson, Emily, Sidhu, Roger, Hamid, Omid
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
489 TWT-101: a phase 1 study of the novel HPK1 inhibitor CFI-402411 in patients with advanced cancer
Hamid, Omid, Bendell, Johanna, Fu, Siqing, Papadopoulos, Kyriakos, Wang, Judy, Ma, Brigette, Spreafico, Anna, Spira, Alexander, Bray, Mark, Fletcher, Graham, Michelson, Glenn, Roberts-Thomson, Emily
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)
Borthakur, Gautam, Jonas, Brian A., Roberts-Thomson, Emily L, Michelson, Glenn C., Bray, Mark R
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Early Experience of the Peer Advocate Program: Using Quality Improvement to Optimize Behavioral and Communication Disconnect in the Operating Room
Eckhouse, Shaina R, Huston, Margaret, Smith, Eileen R, Thomson, Emily, Theodorou, Danielle, Chilson, Kelly, Osborn, Tiffany M, Ogden, M. Allison, Hoffman, Russell, Martin, Jackie L
Published in Journal of the American College of Surgeons (05.09.2024)
Published in Journal of the American College of Surgeons (05.09.2024)
Get full text
Journal Article
TWT-203: Phase 1b/2 dose-confirming study of CFI-402257 as a single agent in advanced solid tumors and in combination with fulvestrant in patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 and endocrine therapy
Wesolowski, Robert, Bray, Mark R., Michelson, Glenn C., Roberts-Thomson, Emily L., Denny, Trisha, Cescon, David W.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)
Jonas, Brian A., Yee, Karen, Koller, Paul B., Brandwein, Joseph, Mims, Alice S., Michelson, Glenn C., Nguyen, Linh, Bray, Mark R, Roberts-Thomson, Emily L, Borthakur, Gautam
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)
Jonas, Brian A., Yee, Karen, Mims, Alice, Koller, Paul B., Brandwein, Joseph, Roboz, Gail J., Michelson, Glenn, Nguyen, Linh, Bray, Mark R, Roberts-Thomson, Emily, Sidhu, Roger, Borthakur, Gautam
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article